Open access

Alterations of Mitochondria and Golgi Apparatus Are Related to Synaptic Pathology in Alzheimer's Disease

Written By

Stavros J. Baloyannis

Submitted: April 20th, 2012 Published: May 15th, 2013

DOI: 10.5772/56079

Chapter metrics overview

2,566 Chapter Downloads

View Full Metrics

1. Introduction

Alzheimer’s disease (AD) is an insidiously progressive severe presenile and senile dementia, involving a number of cellular and biochemical mechanisms. AD affects millions of humans as the most common cause of cognitive decline worldwide, in addition to being a main medical challenge for aging population. From the clinical point of view, AD is mostly characterized by age-dependent inexorably progressing cognitive decline, affecting memory primarily associated with behavioral and mood disorders, which increasingly appear as the disease advances [1]. From the neuropathological point of view, AD is mostly characterized by selective neuronal loss [2, 3], marked synaptic alterations [4–6], morphological mitochondrial abnormalities [7, 8], tau pathology [9] resulting in neurofibrillary tangles (NFT) composed of hyperphosphorylated tau [10], inflammatory responses and by extracellular extensive deposits of polymers of Aβ peptide, in the form of neuritic plaques, which are a main hallmark of AD [11, 12]. These are dispersed in the neocortex, the hippocampus, and many subcortical structures, which play an important role in cognition. In addition, AD is characterized ultrastructurally by organelle pathology involving mostly the microtubules, the mitochondria, and Golgi apparatus [13].

Most studies have revealed that the main pathological criteria for AD, namely the neuritic plaques and neurofibrillary tangles, can account for 40%–70% of the cognitive impairment seen in advanced age, though additional cerebrovascular changes [14, 15] contribute greatly in plotting the dramatic profile of AD.

The two main hypotheses of AD - the amyloid cascade hypothesis, introduced in 1991 [16, 17] and the Tau protein hypothesis, are still subjects of extensive research and debate.The production and accumulation of Aβ peptide, a pathogenic factor leading to AD development, are the result of the post-translational proteolysis of the APP [18], by concerted actions of β- and γ-secretases [19].

The amyloidogenic pathway for APP is initiated by β- site amyloid precursor protein- cleavage enzyme 1 (BACE- 1), resulting in the generation of the intermediate product sAPPβ [20]. γ -Secretase activity is substantial for the cleavage of the transmembrane domain, releasing the Aβ peptide and the APP intracellular domain. Generation of Aβ peptide may occur in the endoplasmic reticulum (ER), trans-Golgi network [21], in lysosomes and on the surface of the cell, whereas its intracellular accumulation has been mostly detected in the majority of neurons in the endoplasmic reticulum, the mitochondria [22], the lysosomes, the multivesicular bodies, associated with synaptic pathology [23]. Many risk factors may affect APP protein metabolism and Aβ peptide production, mainly in late-onset AD. In addition changes in cellular protein homeostasis and aspects of protein folding or misfolding [24] are also linked to AD pathogenesis [25].

All the biochemical phenomena, which may occur within the spectrum of pathogenetic mechanisms in Alzheimer’s disease affect the brain metabolic activity reasonably, since increasing evidence from functional neuroimaging plead in favor of the global and regional disruptions in brain metabolism in advanced cases of AD [26].

From the etiological point of view, it would be hypothesized that the multiple genetic loci [27, 28], associated with familial Alzheimer’s disease would plead in favor of the heterogeneity of the disease and support the idea that the phenomenological profile of Alzheimer’s disease may be the final consequence of various metabolic, neurochemical, and morphological alterations, based on a broad genetic background [29]. Although the majority of familial or inherited AD, which manifests at an early age, are often associated with mutations in AβPP [30], the numerous sporadic ones, which manifests usually at later stages of the life, are proved to be multifactorial, including induced expression of AβPP [31] by pathological stimuli, environmental factors, as well as deprivation of trophic factors. The eventual accumulation of Aβ peptide at synaptic terminals may be associated with synaptic damage, resulting in cognitive decline in patients with AD [32]. Moreover the increased risk of AD in sporadic cases, whenever a maternal relative is afflicted with the disease, pleads reasonably in favor of a maternally derived predisposition, which might be related to mutations of mitochondrial DNA (mtDNA) [33, 34].

1.1. Mitochondria in Alzheimer’s disease

Mitochondria are highly dynamic ATP-generating organelles, which play an essential role in many cellular functions, such as alteration of reduction-oxidation potential of cells, free radical scavenging, intracellular calcium regulation and activation of apoptotic process. Mitochondria are unique amongst cellular organelles, since they dispose their own, spiral, double-stranded DNA (mtDNA), which is mostly inherited from the maternal line. The number of mitochondria is very high in neurons and especially in synaptic terminals, since they are the major energy generators for the cell biological processes and the synaptic activity, through tricarboxylic cycle and oxidative phosphorylation. The shape and size of mitochondria are not stable, since they undergo continual fission and fusion leading to their fragmentation or elongation accordingly.

Mitochondrial dysfunction might contribute to Aβ neurotoxicity and is also associated with oxidative stress, which may play an important role in the early stages of pathogenetic mechanisms in AD [35-37], presumably prior to the onset of the cognitive dysfunction, since a substantial body of evidence suggests that mitochondria play a crucial role in ageing-related neurodegenerative diseases [38].

Mitochondria may be the target for amyloid precursor protein (APP) and Aβ peptide, which might play an important role in impairing mitochondrial dynamics [39]. During AD processes accumulation of APP occurs mostly in the mitochondrial import channels, inducing mitochondrial functional impairment [40]. APP could not be processed to generate Aβ peptide locally [41] although a fraction of active γ-secretase is associated with mitochondria [42].

In the mitochondria, Aβ peptide uptake is mediated by the translocase, which is located in the outer mitochondrial membrane (TOM) [43]. Then Aβ peptide is accumulated mostly in the outer mitochondrial membrane, the inter membrane and the matrix and interacts with large number of proteins inside mitochondria, leading eventually to mitochondrial dysfunction, whenever substantial amount of molecules of Aβ peptide would be produced near mitochondria [44].

It is important to emphasize that mitochondrial alterations are associated with synaptic loss in AD patients, even before amyloid plaques are detected [32, 45]. Morphological and morphometric studies revealed that at early stages of AD the number of mitochondria in synaptic terminals is dramatically decrease and their structural pattern changes [45]. That modification might be attributed to enhanced nitrosative stress, generated by Aβ peptide, leading to mitochondrial fission, which is followed by mitochondrial depletion, resulting in synaptic degeneration eventually [46].

1.2. Golgi apparatus in Alzheimer’s disease

Golgi apparatus plays an important role in the pathogenesis of AD [13, 47], since it is associated with protein trafficking. All newly synthesized proteins, which are used for fast axoplasmic transport are processed practically through the vesicles and the cisternae of Golgi complex [48]. From the first its visualization by Camillo Golgi, in 1898, Golgi apparatus has been subject of intense morphological and neurochemical research.

The electron microscopy study of the mammalian Golgi apparatus has revealed that it consists of stapled cisternae, which serve for the modification of newly synthesized proteins and lipids. At the entrance site of the Golgi apparatus, namely the cis-Golgi, numerous clusters of vesicles and tubular structures form an intermediate chain between the smooth endoplasmic reticulum and the Golgi stack. The exit site, the so called trans-Golgi network (TGN) is the main site of sorting proteins to distinct cellular destinations. Bi-directional traffic between the Golgi apparatus and the endosomal system sustains the functions of the trans-Golgi network (TGN) in secretion and organelle biogenesis [49].

The function of the Golgi complex consists mainly on vesicular transport, involving constant membrane fission and fusion, mediated by GTPases, coat proteins, Rabs, tethers and SNARE proteins, respectively, as it was documented from studies on glycosylation enzymes [50]. The activity of γ-secretase, which consists of presenilins (PSs) [51], nicastrin [52,53], pen-2 [54] and the aph proteins [54,55], is closely related with the function of Golgi complex, since it requires the presenilin-dependent trafficking of nicastrin, through the Golgi apparatus [56].

It was hypothesized that the passage of nicastrin and other components of the γ-secretase complex through Golgi apparatus is essential for the molecular stabilization and the protease activity [56]. In addition APP, which is normally synthesized in the endoplasmic reticulum (ER), is transported to trans-Golgi network (TGN) for trafficking to the cell surface [57, 58], or to synaptic terminals. APP is transported by fast axonal transport, been recycled back for further trafficking or final storing within the lysosomal system [59], in view that TGN generates transport vesicles bound for distinct domains of the plasma membrane and early endosomes. Whereas a small proportion of APP molecules are delivered to the plasma membrane and then cleaved by α-secretase into non-amyloidogenic fragments, the majority of APP molecules undergo degradation, following amyloidogenic pathway in the trans-Golgi network [59].

Advertisement

2. Material and methods

2.1. Patients

We studied the hippocampus, the acoustic and the visual cortices, the thalamus, the globus pallidus, the locus coeruleus, the red nucleus, the hypothalamus and many regions of the cerebellar cortex in ten brains of patients who suffered from AD, four men and six women, aged 62–87 years, who fulfilled the clinical, neuropsychological, and laboratory diagnostic criteria of AD.

The mean education of the patients was 15.2 years, and all of them spoke their native language fluently. Screening procedures were applied, which included medical history, medical examination, cardiological investigation, physical neurologic assessment, psychiatric and neuropsychological examinations. All the patients underwent EEG, carotid duplex Doppler, computerized tomography (CT) scanning and magnetic resonance imaging (MRI) of the brain, and single-photon emission computed tomography (SPECT).

The mental status of the patients was assessed by Mini mental State Examination (MMSE) and dementia rating scale (DRS) [60] and ADAS-COX test.

The cause of death of the patients was heart arrest, following to cardiac infarct one to seven months after the final neurological assessment. The postmortem examination of each one of the cases was performed within 6 h after death.

2.2. Electron microscopy

Small samples (2×2×2 mm) from the hippocampus, the acoustic and the visual cortices, the thalamus, the globus pallidus, the locus coeruleus, the red nucleus, the hypothalamus and from many regions of the cortex of the cerebellar hemispheres and the vermis were excised and immediately immersed in Sotelo’s fixing solution, composed of 1% paraformaldehyde, 2.5% glutaraldehyde in cacodylate buffer 0.1 M, adjusted at pH 7.35. Then they were postfixed by immersion in 1% osmium tetroxide for 30 min at room temperature and dehydrated in graded alcohol solutions and propylene oxide.

Thin sections were cut in a Reichert ultratome, contrasted with uranyl acetate and lead citrate, and studied in a Zeiss 9aS electron microscope.

We studied the morphology of the mitochondria, the Golgi apparatus, and the synapses and we proceeded to morphometric estimations at electron microscope on micrographs of a standard magnification of 56. 000 X.

2.3. Light microscope, Golgi staining, Golgi-Nissl method

The remaining parts of the above-mentioned areas of the brain and the cerebellum were processed for silver impregnation techniques, according to rapid Golgi method.

Thus, after a four-week fixation in formalin they were immersed in potassium dichromate (7 g potassium dichromate in 300 mL water) for 10 days. Then they were immersed in 1% silver nitrate for 10 days. Following a rapid dehydration in graded alcohol solutions, the specimens were embedded in paraffin and cut, some of them at 100 μ and some at 25 μ, alternatively. Many sections of 25 μ were stained also with methylene blue, according to Golgi-Nissl method. All the sections were mounted in permount, between two cover slips and were studied in a Zeiss Axiolab Photomicroscope.

We estimated the dendritic arborization, the morphology and the number of the dendritic branches, and the morphology of the dendritic spines in light microscope on sections stained according to rapid Golgi and Golgi-Nissl methods

2.4. Statistical analysis

Statistical analysis was based on the t-test on the basis of 5000 mitochondria and 600 Golgi apparatus from 30 specimens of AD brains and 30 specimens of normal control brains.

Advertisement

3. Results

3.1. Silver impregnation techniques

The silver impregnation technique or black reaction (reazione near) according to Golgi [61] is a simple and easy histological procedure that enables the visualization of the three-dimensional morphology of neurons and glial cells. Santiago Ramón y Cajal has been applying Golgi technique extensively for the histological analysis of the CNS, defending successfully the “neuron doctrine” and sharing with Camillo Golgi the Nobel Prize in 1906. After 140 years from its first application, the Golgi technique continues to remain a very useful and valuable method in neuropathology for the morphological and morphometric estimation of neuronal circuits at the early stages of the degenerative processes of the brain [62].

The application of silver impregnation technique in our specimens revealed neuronal loss and marked abbreviation of the dendritic arborization in all the layers of the acoustic and the visual cortices, the hippocampus, the thalamus, the globus pallidus, the locus coeruleus, the red nucleus, the hypothalamus (Fig.1), the cerebellar cortex (Fig.2) and the vermis of the cerebellum (Fig.3). The layer I, of the acoustic and visual cortices, which includes Cajal-Retzius cells, which normally protrude very long horizontal axonal profiles with substantial number of collaterals [63. 64], was practically empty of neurons in patients who suffered from AD, in contrast to normal controls.

Figure 1.

Neuron from the Hypothalamus of a case of AD, showing abbreviation of dendritic arborization and marked loss of dendritic spines (Golgi staining 2,400X)

Figure 2.

Purkinje cells from the cerebellar hemisphere of a case of AD, demonstrating marked abbreviation of the dendritic arborization and considerable loss of dendritic spines (Golgi staining 2,000X).

Loss of tertiary dendritic branches was also noticed in the acoustic and visual cortices in all of the specimens. Abbreviation of the dendritic arborization was mostly prominent in neurons of layers III and V of the acoustic and visual cortices, the pyramidal neurons of the hippocampus, the polyhedral neurons of the locus coeruleus and in Purkinje cells of the cerebellar cortex, which demonstrated also a marked decrease of the number of dendritic spines (Fig.3) in comparison with the normal controls.

Figure 3.

Purkinje cells from the vermis of the cerebellum of a case of AD, showing dramatic reduction of dendritic branches and loss of dendritic spines (Golgi staining 3,100X)

In addition, the axonal collaterals in layers III, IV, V, and VI of the acoustic and visual cortices were dramatically decreased in comparison with the normal controls.

The decrease of the branches of the apical dendrites of the cortical neurons as well as decrease in spine density was widespread phenomena seen in the large majority of neurons of the acoustic (Fig.4) and the visual cortices, in the hippocampus, the thalamus, the globus pallidus, the red nucleus, the locus coeruleus, the hypothalamus and the cerebellar cortex (Figs 1,2).

Figure 4.

Neurons from the acoustic cortex of a case of AD, showing marked decrease of tertiary dendritic branches and tremendous loss of spines (Golgi staining 2,400X).

3.2. Electron microscopy

Electron microscopy is the most valuable and precise method for the morphological and morphometric study of the cell organelles, the synapses, the dendritic spines as well as the neuron- glial relationships in the CNS both in health and disease.

In our study, the electron microscopy revealed pathological alterations of the dendritic spines and impressive decrease in spine density in the secondary and tertiary dendritic branches in all of the layers of the acoustic and visual cortices.

The reduction in spine size was prominent in neurons of layers II, III, and V of the acoustic cortex. A substantial number of dendritic spines demonstrated large multivesicular bodies, abnormal spine apparatus, and mitochondria, which were characterized by marked morphological alterations. Morphological alterations of the dendritic spines were also seen in the pyramidal neurons of the hippocampus, the large polyhedral neurons of the thalamus, the globus pallidus, the polyhedral neurons of the locus coeruleus as well as the Purkinje cells of the cerebellar hemispheres (Fig.5). Giant elongated spines were mostly seen in the hippocampus and in the Purkinje cells of the cerebellum. In a large number of presynaptic terminals of the acoustic and visual cortices of patients who suffered from AD, the ultrastructural study has revealed an considerable polymorphism and pleomorphism of the synaptic vesicles, which were dramatically decreased in number in comparison with normal controls.

Figure 5.

Synaptic alterations in the cerebellar cortex in a case of AD. Impressive poverty of synaptic vesicles is noticed at the presynaptic terminals associated with mitochondrial alterations and disruption of the spinal apparatus (Electron micrograph 128,000X).

Substatial poverty of the synaptic vesicles was particularly seen in the presynaptic terminals in layers III, IV, and V of the acoustic and visual cortices, as well as in the mossy fibers of the cerebellar cortex. Decrease of the number of synaptic vesicles associated with polymorphism of the remained vesicles was noticed in the hippocampus, the thalamus, the locus coeruleus, and the parallel and climbing fibers of the cerebellar cortex.

Mitochondrial pathology was demonstrated in the majority of the dendritic spines in all of the specimens. That consisted of substantial change of mitochondrial shape and size, fragmentation of cristae, and accumulation of osmiophilic material in a considerable number of mitochondrial profiles (Fig.6). Many dendritic branches included mitochondria, which showed an unusual polymorphic arrangement of the cristae, which either showed a concentric configuration or they were arranged in a parallel way to the long axis of the organelle. Some Purkinje cell dendrites (Fig.6) and a substantial number of climbing fibers included very large elongated mitochondria. Small round mitochondria intermixed with dense bodies were seen in association with fragmentation or dilatation of the cisternae of the Golgi apparatus in the soma of a considerable number of neurons of the visual cortex (Fig.7), the hippocampus, the locus coeruleus, the red nucleus, the polyhedral neurons of globus pallidus, and the Purkinje cells in AD brains.

Figure 6.

Abnormal mitochondria in a dendritic profile of Purkinje cell in a case of AD. The disruption of the cristae is a prominent phenomenon (Electron micrograph 128,000X).

Figure 7.

Elongated mitocondria and mitochondria in fusión, intermixed with dense bodies and dilated cisternae of Golgi apparatus in a case of AD (Electron micrograph 25,000X).

It is worth to emphasize that morphological alterations of the mitochondria were also seen in the soma of astrocytes, the perivascular processes, and the astrocytic sheaths in AD brains, in contrast to normal controls.

From the morphometric point of view the ellipsoid mitochondria of the dendritic spines in normal control brains appear to have an average diameter of 650 ± 250 nm and a mean axial ratio of 1.9 ± 0.2. The round or global mitochondria appeared to have in normal controls a mean radius of 350 nm. In AD brains, the ellipsoid mitochondria of the neurons in acoustic and visual cortices appear to have an average diameter of 480 ± 250 nm and a mean axial ratio of 1.7 ± 0.2. The round mitochondria appear to have a mean radius of 280 nm (Chart.1).

Chart 1.

Decrease of the diameter of mitochondria in the visual cortex in Alzheimer’s cases in comparison with normal controls.

In the majority of Purkinje cells of the cerebellum, in the hippocampal neurons and in neurons of the parietal, frontal, acoustic and visual cortices the Golgi apparatus was mostly fragmented and atrophic (Fig.8) in comparison with normal controls.

Figure 9.

Fragmentation of the cisternae of the Golgi apparatus in a Purkinje cell of the cerebellar cortex of a case of AD (left) (Electron micrograph 128,000). Normal control (right) (Electron micrograph 65,000X)

It is important to underline that the fragmentation of the Golgi apparatus was seen in neurons which did not showed any tau pathology, such as accumulation of intracellular NFTs, and were located in areas with minimal deposits of Aβ peptide. However the atrophy and the fragmentation of Golgi apparatus coexisted with mitochondrial alterations and dendritic and spinal pathology in the large majority of neurons (Fig.9).

Figure 9.

Degeneration of dendritic spine in the visual cortex of a case of AD (Electron micrograph 130,000X)

Advertisement

4. Discussion

The mitochondria, which are the only nonnuclear constituents of the cell with their own DNA (mtDNA), having machinery for synthesizing RNA and proteins, are critical to homeostasis of the cell, by virtue of providing most of the energy for cellular processes, since energy, realized by oxidative phosphorylation, comes through the mitochondria, which generate most of the cell’s supply of ATP. Mitochondria are also critical regulators of cell apoptosis, as being involved in a considerable number of neurodegenerative diseases [65, 66],

From the morphological point of view the shape and size of the mitochondria are highly variable [67], depending on fission and fusion [68]. Their morphology is occasionally controlled by cytoskeletal elements, namely the neurofilaments and the microtubules [69]. The change of the mitochondrial shape occurs mostly through their move to axons, dendrites, and synaptic terminals via anterograde transport [70]. During the various neuronal processes approximately one-third of the mitochondria are in motion along microtubules and actin filaments [71–73]. Mitochondrial motility and accumulation are coordinated, since mitochondria are transported to regions where ATP consumption and necessity for energy are particularly high, as it occurs in the synapses, which have high energy demand reasonably, for serving neuronal communication [74].

Mitochondrial alterations and dysfunction have been reported in several neurodegenerative diseases [75] mostly associated with oxidative damage [76-78] and vascular lesions [79]. Oxidative stress is mostly related with the accumulation of Aβ peptide in the neocortex [80, 81], playing an important role in the pathogenesis of AD [82], since it is not only involved in the formation of senile plaques and in damage to the proteins of NFT [83], but also induces extensive damage to the cytoplasm of neuronal populations vulnerable to death [84].

It is also well documented that Aβ peptide may increase mitochondrial reactive oxygen species (ROS) production [85, 86], causing further impairment of mitochondrial function [87], since the lack of histones in mitochondrial DNA renders them a vulnerable target to oxidative stress. In major examples of neurodegenerative diseases, there is strong evidence that mitochondrial dysfunction occurs early and acts causally in disease pathogenesis. Mutations in mitochondrial DNA and oxidative stress, on the other hand, may contribute to ageing [88, 89], which is the substantial biological background for the majority of the neurodegenerative diseases [65].

Mitochondrial dysfunction has been associated with energy crisis of the cell and excitotoxic cell death and is considered to be of substantial importance in the cascade of phenomena, which eventually lead to apoptosis. Some observations in early cases of AD [90] indicate that morphological alterations of the mitochondria and oxidative damage may be one of the earliest events.

The morphological alteration of the mitochondria seen in subcortical centers, such as in the thalamus, the globus pallidus, the red nucleus, the hypothalamus and the locus coeruleus, pleads in favor of a generalized mitochondrial dysfunction in AD, which may be associated with wide neuronal loss and synaptic alterations, seriously affecting the mental faculties, which are basically related to extensive neural networks [91] and synaptic activity. Moreover, an impressive number of disease-specific proteins interact with mitochondria. Well-documented studies [92] demonstrate that a significant amount of the N-terminal domain of APP targeted the mitochondria of cortical neurons and select regions of the brain of a transgenic mouse model for AD. The accumulation of trans membrane-arrested APP blocked protein translocation, disrupted mitochondrial function, and impaired brain energy metabolism.

In AD it may be considered that mitochondria-associated Aβ peptide may directly cause neurotoxicity [93, 94]. Mitochondrial dysfunction, therefore, might be a hallmark of amyloid-beta-induced neuronal toxicity in Alzheimer’s disease [95]. The binding site for amyloid beta peptide has been identified as alcohol dehydrogenase in the matrix space of the organelle. Recent evidence also suggest that PS1, PS2, APP, and γ-secretase activity are not homogeneously distributed in the ER, but rather are enriched in mitochondria-associated ER membranes (ER-MAMs or MAMs), which is a dynamic sub-compartment of the ER, which is connected with mitochondria [96]. Mitochondria and ER are closely connected in several functions such as transfer of Calium, lipid metabolism, the control of apoptosis and autophagy [96]

Many morphological alterations of AD could be well linked to mitochondria changes, since blockage of mitochondrial energy production shifts APP metabolism to the production of more amyloidogenic forms of amyloid [97]. In addition amyloid beta peptide promotes permeability transition pore in brain mitochondria [85, 98]. It is important to mention that many protein systems are also essential in mitochondrial function and morphological integrity as well as in binding to the cytoskeleton [99]. Mitochondrial porin is an outer-membrane protein that forms regulated channels (Voltage-Dependent Anionic Channels) between the mitochondrial inter-membrane space and the cytosol [100]. Porin may play an important role in binding to neurofilaments and microtubules, since porin-rich domains contain most of the binding sites for MAP2 [101, 102]. In addition, preselinin-2 modulates endoplasmic reticulum-mitochondrial interactions [103], a fact that would plead in favor of the crucial role that mitochondria play in the pathogenetic cascade of AD.

Recent studies reported increased mitochondrial fission and decreased fusion, due to increased amyloid beta (Aβ) interaction with the mitochondrial fission protein Drp 1, inducing increased mitochondrial fragmentation, impaired axonal transport of mitochondria and synaptic degeneration in AD [104]. In addition, the interaction of the voltage-dependent anion channel 1 protein (VDAC1) with Aβ peptide and phosphorylated tau block mitochondrial pores, leading to mitochondrial dysfunction in AD [105].

The number of the mitochondria varies, according to energy state of the cell. Some evidence suggests that the mitochondria redistribute towards the dendritic profiles, in response to stimulation as a manifestation of synaptic plasticity [106]. Normally, a limited number of dendritic spines contain mitochondria, which are mostly small and round, which are increased in number inside the dendritic branches during the synaptogenesis. Decrease in energy metabolism and altered cytochrome c oxidase (CytOX) activity are among the earliest detectable defects in AD [107], affecting presumably neuronal plasticity and synaptogenesis. Some observations suggest that mitochondrial cytochrome c oxidase may be inhibited by a dimeric conformer of Aβ35, a phenomenon which further emphasizes the role of the Aβ peptide on the mitochondrial dysfunction in AD [108].

Among the ongoing therapeutic efforts [109], those targeting basic mitochondrial processes, such as energy metabolism, free-radical generation, or specific interactions of disease-related proteins with mitochondria, hold great promise. On the basis of the mitochondrial pathology, in the pathogenetic spectrum in AD, new strategies inducing protection to mitochondria by the administration of efficient antioxidant factors could be introduced in the treatment of early cases of AD.

Golgi apparatus, on the other hand plays a very important role in posttranslational modifications, transport, and targeting of large number of proteins, which participate in axoplasmic transport or are transported to plasma membrane, to lysosomes, to synaptic terminals and dendritic spines. A substantial body of evidence suggest that Golgi complex is involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) [110-112] and AD, as it is well documented by highly specific immunocytochemistry techniques [47, 113].

The size of the Golgi apparatus may be an index of neuronal activity. Thus the fragmentation of the cisternae of Golgi apparatus may be associated with impaired trafficking of proteins to synapses and dendritic spines resulting in synaptic degeneration and cognitive impairment eventually. It is well documented that the trans-Golgi network (TGN) is the major sorting structure of the secretory pathway and the main site of intersection with the endo-lysosomal system [48, 49]. Current data clearly suggest that perturbations to the endosomal retrograde sorting pathway promote the production of Aβ. The recent discovery of an integral membrane protein, Gamma-secretase activating protein (GSAP) [114,115],which associates with γ-secretase, APP and promotes the production Aβ peptide may provide an important link for understanding how γ-secretase is directed to APP and help to clarify the site(s) of Aβ production. GSAP might be also an ideal target for designing γ-secretase modulators in an attempt for treating AD [116,117].

References

  1. 1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's and Dementia. 2010; 6: 158–194.
  2. 2. Wisniewski H M, Wegiel J, Kotula L. Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Neuropathology and Applied Neurobiology, 1996; 22: 3–11.
  3. 3. Duyckaerts C, Delatour B,. Potier M C. Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009; 118: 5–36.
  4. 4. Baloyannis S, Costa V, Arnaoutoglou A, Arnaoutoglou H. Synaptic alterations in the molecular layer of the cerebellum in Alzheimer's disease. Neuropathology and Applied Neurobiology 1996; 22: 78–79.
  5. 5. Baloyannis S J, Manolidis S L, Manolidis L S. The acoustic cortex in Alzheimer's disease. Acta Oto-Laryngologica. 1992; 494: 1–13.
  6. 6. Baloyannis S J, Manolidis S L, Manolidis L S. Synaptic alterations in the vestibule-cerebellar system in Alzheimer's disease- a Golgi and electron microscope study. Acta Oto-Laryngolo-gica 2000; 120: 247–250.
  7. 7. Baloyannis S J, Costa V. Michmizos D. Mitochondrial alterations in Alzheimer's disease. American Journal of Alzheimer's Disease and other Dementias. 2004; 19: 89–93.
  8. 8. Baloyannis S J, Baloyannis J S. Mitochondrial alterations in Alzheimer's disease. Neurobiology of Aging. 2004; 25: 405–406.
  9. 9. Iqbal K, Liu F, Gong C X, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Current Alzheimer Research.2010; 7: 656–664.
  10. 10. Mattson M P. Pathways towards and away from Alzheimer's disease. Nature. 2004; 430: 631–639.
  11. 11. Dickson D M. The pathogenesis of senile plaques. Journal of Neuropathology and Experimental Neurology1997; 56: 321–339.
  12. 12. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. Journal of Clinical Investigation. 2005; 115: 1121–1129.
  13. 13. Baloyannis S. The Golgi apparatus of Purkinje cells in Alzheimer's disease. in Neuropathology Back to the Roots, J. Bohl, (Ed)., pp. 1–10, Shaker Vertag, Aachen, Germany, 2002.
  14. 14. Dolan D, Troncoso J, Crain B, Resnick S, Zonderman A, O’Brien R. Age, dementia and Alzheimer’s disease in the BLSA. Brain. 2010; 133: 2225–2231.
  15. 15. Baloyannis SJ, Baloyannis IS The vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy. J Neurol Sci. 2012; 322:117-121.
  16. 16. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991; 12: 383–388.
  17. 17. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297:353–356
  18. 18. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell. 2005; 120:545–555.
  19. 19. Selkoe D J. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 2001; 81: 741–766.
  20. 20. Greenfield J, Tsai J, Gouras G, Hai B, Thinakaran G, Checler F, Sisodia S, Greengard P, Xu H. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 742–747.
  21. 21. Takahashi R, Milner T, Li F, Nam E, Edgar M, Yamaguchi H, Beal M, Xu H, Greengard P, Gouras G. Intraneuronal Alzheimer A42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 2002; 161: 1869–1879.
  22. 22. Caspersen C, Wang N, Yao Y, Sosunov A, Chen X, Lustbader J W, Xu H W, Stern D, McKhann G, Yan S D. Mitochondrial A: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 2005;19: 2040–2041.
  23. 23. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008; 192:106–113.
  24. 24. Dobson CM Protein folding and misfolding. Nature 2003; 426:884–890.
  25. 25. Morawe T, Hiebel C, Kern A, Behl C Protein Homeostasis, Aging and Alzheimer’s Disease. Molecular Neurobiology. 2012; 46: 41-54.
  26. 26. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med 1997:38: 925–928.
  27. 27. Price D L, Sisodia S S. Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience. 1998; 21: 479–505.
  28. 28. Tanzi R E. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. Journal of Clinical Investigation. 1999; 104: 1175–1179.
  29. 29. Caruso C, Franceschi C, Licastro F. Genetics of neurodegenerative disorders. The New England Journal of Medicine.2003; 349: 193–194.
  30. 30. Hashimoto Y, Niikura T, Ito Y, Nishimoto I. Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein. Journal of Biological Chemistry. 2000; 275: 34541–34551.
  31. 31. Selkoe D J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. Journal of Alzheimer's Disease.2001; 3: 75–80.
  32. 32. Reddy P H, Beal M F.Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine. 2008; 14: 45–53.
  33. 33. Shoffner J M, Brown MD, Torroni A, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics, 1993; 17: 171–184.
  34. 34. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. Journal of Neuroscience. 2001; 21: 3017–3023.
  35. 35. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787–795.
  36. 36. Manczak M, Anekonda T S, Henson E, Park B S, Quinn J, Reddy P H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics 2006; 15: 1437–1449.
  37. 37. Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem 2012; 120: 419–429.
  38. 38. Beal MF, Hyman B T, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends in Neurosciences 1993; 16:125–131.
  39. 39. Lin M T, Beal M F. Alzheimer’s APP mangles mitochondria. Nat. Med. 2006; 12: 1241–1243.
  40. 40. Anandatheerthavarada H K, Biswas G, Robin M A, Avadhani N G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. Journal of Cell Biology. 2003; 161: 41–54
  41. 41. Pagani L, Eckert A. Amyloid-Beta Interaction with Mitochondria. International Journal of Alzheimer’s Disease Volume 2011, Article ID 925050, 12 pages doi:10.4061/2011/925050.
  42. 42. Hansson C A, Fryckman S, Farmery M. R, Tjernberg L O, Nilsberth C, Pursglove S E, Ito A, Winblad B, Cowburn R F, Thyberg J, Ankarcrona, M. Nicastrin, presenilin,APH-1, and PEN-2 form active γ-secretase complexes in mitochondria J. Biol. Chem. 2004; 279: 51654–51660.
  43. 43. Petersen H, Alikhani CA, Behbahani N, Wiehager H, Pavlov B, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. The amyloid beta peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U.S.A. 2008; 105:13145–13150.
  44. 44. Caspersen C, Wang N, Yao Y, Sosunov A, Chen X, Lustbader J W, Xu H W, Stern D, McKhann G, Yan S D. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 2005;19: 2040–2041.
  45. 45. Baloyannis SJ. Mitochondria are related to synaptic pathology in Alzheimer's disease. Int J Alzheimers Dis. 2011; 2011:305395. Epub 2011 Sep 12
  46. 46. Cho D H, Nakamura T, Fang J. et al., S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009; 324:102–105.
  47. 47. Stieber A, Mourelatos Z, Gonatas N K. In Alzheimer's Disease the Golgi Apparatus of a Population of Neurons without neurofibrillary Tangles Is Fragmented and Atrophic. American Journal of Pathology. 1996; 148: 415-426.
  48. 48. Hammerschlag R, Stone GC, Bolen FA, Lindsey JD, Ellisman MH. Evidence that all newly synthesized proteins destined for fast axonal transport pass through the Golgi apparatus. J Cell Biol. 1982; 93:568-575
  49. 49. Burd C G. Physiology and Pathology of Endosome-to-Golgi Retrograde Sorting Traffic 2011; 12: 948–955.
  50. 50. Duncan JR, Kornfeld S. Intra cellular movement of two mannose 6-phosphate receptors: return to the Golgi apparatus. J Cell Biol. 1988; 106: 617–628.
  51. 51. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for gamma-secretase cleavage of beta-APP and trans-membrane cleavage of Notch-1. Nat Cell Biol. 2000; 2: 463-465.
  52. 52. Chung H M, Struhl G. Nicastrin is required for Presenilin mediated trans-membrane cleavage in Drosophila. Nat Cell Biol. 2001; 3: 1129-1132.
  53. 53. Hu Y, Ye Y, Fortini M E. Nicastrin is required for gamma secretase cleavage of the Drosophila notch receptor. Dev Cell 2002; 2: 69-78.
  54. 54. Francis R, McGrath G, Zhang J, Ruddy D A, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis M C. et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta APP, and presenilin protein accumulation. Dev Cell. 2002; 3: 85-97.
  55. 55. Goutte C, Tsunozaki M, Hale V A, Priess J R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl. Acad. Sci. US A 2002;99: 775-779.
  56. 56. Herreman An, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K. Mueller U, Annaert W, De Strooper B. g-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. Journal of Cell Science. 2003; 116:1127-1136.
  57. 57. Sisodia SS. Beta-amyloid precursor protein cleavage by a membrane bound protease. Proc Natl Acad Sci USA 1992; 89:6075–6079.
  58. 58. Vetrivel KS, Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments, Neurology 2006;66: 69-73.
  59. 59. Zheng L, Cedazo-Minguez A, Hallbeck M, Jerhammar F, Marcusson J, Terman A. Intracellular distribution of amyloid beta Peptide and its relationship to the lysosomal system. Translational neurodegeneration 2012, 19:1-7.
  60. 60. Mattis S., Dementia Rating Scale Professional Manual, Psychological Assessment Resources, Odessa, Fla, USA, 1988.
  61. 61. Pannese E. The Golgi stain: invention, diffusion and impact on neurosciences. J Hist Neurosci. 1999; 8:132- 140.
  62. 62. Baloyannis SJ. Morphological and morphometric alterations of Cajal-Retzius cells in early cases of Alzheimer’s disease: a Golgi and electron microscope study. Int J Neurosci. 2005; 115:965-80.
  63. 63. Marín-Padilla M. Cajal-Retzius cells and the development of the neocortex. Trends in Neurosciences. 1998; 21: 64–71.
  64. 64. Marín-Padilla M. Three-dimensional structural organization of layer I of the human cerebral cortex: a Golgi study. Journal of Comparative Neurology.1990; 299: 89–105.
  65. 65. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochimica et Biophysica Acta.1998; 1366: 211–223.
  66. 66. Mizuno Y, Ikebe S I, Hattori N.et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochimica et Biophysica Acta. 1995; 1271: 265–274.
  67. 67. Bereiter-Hahn J, Vöth M. Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria. Microscopy Research and Technique.1994; 27:198–219.
  68. 68. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007; 130: 548-562.
  69. 69. Knowles M K, Guenza M G, Capaldi R A, Marcus A H. Cytoskeletal-assisted dynamics of the mitochondrial reticulum in living cells. Proceedings of the National Academy of Sciences USA. 2002; 99: 14772–14777.
  70. 70. Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. Journal of Cell Science. 2005; 118: 5411–5419.
  71. 71. Krendel M, Sgourdas G, Bonder EM. Disassembly of actin filaments leads to increased rate and frequency of mitochondrial movement along microtubules. Cell Motility and the Cytoskeleton. 1998; 40: 368–378.
  72. 72. Leterrier J F, Rusakov D A, Nelson B D, Linden M. Interactions between brain mitochondria and cytoskeleton: evidence for specialized outer membrane domains involved in the association of cytoskeleton-associated proteins to mitochondria in situ and in vitro. Microscopy Research and Technique. 1994; 27: 233–261.
  73. 73. Lifshitz J, Janmey PA, Linden M, McIntosh TK, Leterrier J F. Mechanisms of mitochondria-neurofilament interactions. The Journal of Neuroscience. 2003; 23: 9046–9058.
  74. 74. Brown M R, Sullivan P G, Geddes J W. Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria. Journal of Biological Chemistry. 2006; 281:11658–11668.
  75. 75. Mattson M P, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008; 60: 748–766.
  76. 76. Baloyannis S. Oxidative stress and mitochondria alterations in Alzheimer's disease. Neurobiology of Aging. 21: 264. 2000.
  77. 77. Pereira C, Santos M S, Oliveira C. Involvement of oxidative stress on the impairment of energy metabolism induced by Abeta peptides on PC12 cells: protection by antioxidants. Neurobiology of Disease. 1999; 6: 209–219.
  78. 78. Zhu X, Perry G, Moreira P I. et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease. 2006; 9: 147–153.
  79. 79. Aliev G, Smith M A, Seyidova D. et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathology. 2002; 12:21–35.
  80. 80. Arias C, Montiel T, Quiroz-Baez R, Massieu L. Beta-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Experimental Neurology 2002; 176:163–174.
  81. 81. Nunomura A, Perry G, Aliev G. et al. Oxidative damage is the earliest event in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology 2001; 60: 759–767.
  82. 82. Aliev G. Oxidative stress induced-metabolic imbalance, mitochondrial failure, and cellular hypoperfusion as primary pathogenetic factors for the development of Alzheimer disease which can be used as a alternate and successful drug treatment strategy: past, present and future.CNS and Neurological Disorders—Drug Targets. 2011; 10: 147–148.
  83. 83. Hugon J, Esclaire F, Lesort M, Kisby G, Spencer P. Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions. Drug Metabolism Reviews. 1999; 31: 635–647.
  84. 84. Moreira P I, Cardoso S M, Santos M S, Oliveira C R. The key role of mitochondria in Alzheimer's disease. Journal of Alzheimer's Disease 2006; 9: 101–110.
  85. 85. Moreira PI, Santos MS, Moreno A, Oliveira C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Bioscience Reports. 2001; 21: 789–800.
  86. 86. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiology of Aging. 2000; 21: 455–462.
  87. 87. Mecocci P, Cherubini A, Beal M F. et al. Altered mitochondrial membrane fluidity in AD brain. Neuroscience Letters.1996; 207: 129–132.
  88. 88. Luo Y, Bond J D, Ingram VM. Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proceedings of the National Academy of Sciences USA 1997; 94: 9705–9710.
  89. 89. Hsin-Chen Lee, Yau-Huei Wei. Mitochondria and Aging. Advances in Experimental Medicine and Biology. 2012; 942: 311-327.
  90. 90. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. Journal of Alzheimer's Disease, 2006; 9: 119–126.
  91. 91. Mesulam M M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Annals of Neurology. 1990; 28: 597–613.
  92. 92. Choia K, Kima M, Jea A, Ryua K, Chaea H, Kweona H, Leea C. A Three-Dimensional Study of Ultrastructural Variation of Abnormal Mitochondria in APP/PSEN1 Transgenic Mouse. Brain Microscopy and Microanalysis. 2012; 18 (Supplement S2): 212-213.
  93. 93. Eckert A, Schmitt K, Gotz J. Mitochondrial dysfunction, the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid beta toxicity. Alzheimer's Research and Therapy, 2011; 3:15.
  94. 94. Spuch C, Ortolano S, Navarro C. New Insights in the Amyloid-Beta Interaction with Mitochondria. Journal of Aging Research Volume 2012, Article ID 324968. 9 pages doi: 10. 1155/ 2012/324968
  95. 95. de Brito OM, Scorrano L. An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. EMBO J 2010; 29: 2715–2723.
  96. 96. De Strooper Bart, Scorrano L. Close encounter: mitochondria, endoplasmic reticulum andAlzheimer’s disease The EMBO Journal.2012; 31: 4095–4097.
  97. 97. Crouch P J, Blake R,. Duce J A. et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-β1-42. Journal of Neuroscience 2005; 25: 672–679.
  98. 98. Moreira P I, Santos M S, Moreno A, Rego A C, Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. Journal of Neuroscience Research. 2002; 69: 257–267.
  99. 99. Truscott K, Pfanner N, Voos W. Transport of proteins into mitochondria. Reviews of Physiology, Biochemistry and Pharmacology. 2001; 143: 81–136.
  100. 100. Summersa WAT, Wilkinsb JA, Dwivedib RC, Ezzatib P, Courta DA. Mitochondrial dysfunction resulting from the absence of mitochondrial porin in Neurospora crassa. Mitochondrion. 2012;12: 220–229.
  101. 101. Reddy PH. Is the mitochondrial outer membrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease2013;1832: 67–75.
  102. 102. Calkins M J, Reddy PH. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2011; 1812:1182–1189.
  103. 103. Zampese E, Fasolato C, Kipanyula J, Bortolozzi M, Pozzan T, Pizzo P. Presenilin 2 modulates endoplasmic reticulum (ER)—mitochondria interactions and Ca2+ cross-talk. Proceedings of the National Academy of Sciences USA. 2011; 7: 2777–2782.
  104. 104. Manczak M, Reddy P H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 2012; 21: 2538-2547.
  105. 105. Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet. 2012; 21: 5131-5146.
  106. 106. Li Z, Okamoto K.-I, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004; 119: 873–887.
  107. 107. Cardoso S, Proenca M, Santos S, Santana I, Oliveira C. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiology of Aging 2004; 25:105–110.
  108. 108. Lynch T, Cherny RA, Bush A I. Oxidative processes in Alzheimer's disease: the role of Ab-metal interactions. Experimental Gerontology 2000; 35: 445–451.
  109. 109. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature 2010; 467:95–98.
  110. 110. Gonatas NK, Stieber A, Mourelatos Z, Chen Y, Gonatas JO, Appel SH, Hays AP, Hickey WF, Hauw JJ. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am J Pathol. 1992, 140:731-737.
  111. 111. Mourelatos Z, Hirano A, Rosenquist A, Gonatas NK. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis (ALS): clinical studies in ALS of Guam and experimental studies in deafferented neurons and in f3, f-iminodiproprionitrile axonopathy. Am J Pathol 1994, 144:1288-1300.
  112. 112. Mourelatos Z, Yachnis A, Rorke L, Mikol J, Gonatas NK. The Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 1993, 33:608-615.
  113. 113. Mourelatos Z, Adler H, Hirano A, Donnenfeld H, Gonatas JO, Gonatas NK. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle-specific antibodies. Proc Natl Acad Sci USA. 1990, 87:4393-4395.
  114. 114. Deatherage CL, Hadziselimovic A, Sanders C R. Purification and Characterization of the Human γ-Secretase Activating Protein Biochemistry. 2012; 51: 5153–5159.
  115. 115. Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K. Immunohistochemical characterization of γ-secretase activating protein expression in Alzheimer's disease brains Neuropathology and Applied Neurobiology. 2012; 38: 132–141.
  116. 116. Borgegard T, Jureus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater A-C, Li T, Singh R, Eriksson H, Lundkvist J. First and second generation gamma-secretase modulators (GSMs) modulate Abeta production through different mechanisms. The Journal of Biological Chemistry. 2012; 287: 11810-11819.
  117. 117. Borgegård T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg A-L, Rosqvist S, Serneels L, Svensson S, Olsson F, Jin S, Yan H, Wanngren J, Jureus A, Ridderstad-Wollberg A, Wollberg P, Stockling K, Karlström H, Malmberg Å, Lund J, Arvidsson PI, De Strooper B, Lendah U, Lundkvist J. Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy. The Journal of Neuroscience. 2012; 32: 17297-17305.

Written By

Stavros J. Baloyannis

Submitted: April 20th, 2012 Published: May 15th, 2013